Corcept Therapeutics (CORT) Upgraded at BidaskClub

BidaskClub upgraded shares of Corcept Therapeutics (NASDAQ:CORT) from a hold rating to a buy rating in a research report released on Thursday.

A number of other analysts have also issued reports on CORT. Zacks Investment Research lowered Corcept Therapeutics from a buy rating to a hold rating in a report on Wednesday, January 3rd. Piper Jaffray Companies reaffirmed a buy rating and issued a $24.00 target price on shares of Corcept Therapeutics in a report on Wednesday, October 11th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of Buy and an average target price of $21.00.

Shares of Corcept Therapeutics (CORT) traded down $0.20 during midday trading on Thursday, hitting $20.65. The stock had a trading volume of 1,319,500 shares, compared to its average volume of 1,633,444. The firm has a market cap of $2,360.00, a price-to-earnings ratio of 71.21 and a beta of 1.89. Corcept Therapeutics has a fifty-two week low of $6.70 and a fifty-two week high of $21.00.

Corcept Therapeutics (NASDAQ:CORT) last released its earnings results on Thursday, November 2nd. The biotechnology company reported $0.11 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.13 by ($0.02). The business had revenue of $42.70 million during the quarter, compared to analyst estimates of $41.64 million. Corcept Therapeutics had a net margin of 27.28% and a return on equity of 58.17%. The business’s quarterly revenue was up 96.8% compared to the same quarter last year. During the same period last year, the business earned $0.02 EPS. sell-side analysts forecast that Corcept Therapeutics will post 0.47 EPS for the current year.

In other Corcept Therapeutics news, Director G Leonard Baker, Jr. sold 30,000 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $17.59, for a total value of $527,700.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Robert S. Fishman sold 8,000 shares of the firm’s stock in a transaction that occurred on Monday, January 8th. The shares were sold at an average price of $18.67, for a total value of $149,360.00. Following the completion of the sale, the insider now directly owns 8,000 shares in the company, valued at approximately $149,360. The disclosure for this sale can be found here. Insiders sold a total of 46,000 shares of company stock worth $810,820 in the last ninety days. Insiders own 19.20% of the company’s stock.

Several hedge funds have recently made changes to their positions in CORT. Renaissance Technologies LLC lifted its position in shares of Corcept Therapeutics by 44.4% in the 2nd quarter. Renaissance Technologies LLC now owns 2,683,400 shares of the biotechnology company’s stock worth $31,664,000 after acquiring an additional 824,900 shares during the period. Vanguard Group Inc. lifted its position in shares of Corcept Therapeutics by 18.4% in the 2nd quarter. Vanguard Group Inc. now owns 4,440,064 shares of the biotechnology company’s stock worth $52,394,000 after acquiring an additional 689,554 shares during the period. Teachers Advisors LLC lifted its position in shares of Corcept Therapeutics by 316.9% in the 2nd quarter. Teachers Advisors LLC now owns 817,245 shares of the biotechnology company’s stock worth $9,643,000 after acquiring an additional 621,219 shares during the period. Wells Fargo & Company MN lifted its position in shares of Corcept Therapeutics by 644.4% in the 3rd quarter. Wells Fargo & Company MN now owns 715,261 shares of the biotechnology company’s stock worth $13,805,000 after acquiring an additional 619,180 shares during the period. Finally, Prudential Financial Inc. lifted its position in shares of Corcept Therapeutics by 3,409.5% in the 2nd quarter. Prudential Financial Inc. now owns 633,223 shares of the biotechnology company’s stock worth $7,472,000 after acquiring an additional 615,180 shares during the period. Institutional investors own 64.64% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Corcept Therapeutics (CORT) Upgraded at BidaskClub” was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international trademark and copyright law. The original version of this piece of content can be read at https://ledgergazette.com/2018/01/15/corcept-therapeutics-cort-upgraded-at-bidaskclub.html.

About Corcept Therapeutics

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).

Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply